As filed with the Securities and Exchange Commission on December 22, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSPIRA TECHNOLOGIES OXY B.H.N.LTD. (Exact name of registrant as specified in its charter) State of Israel 3841 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Nu ...

NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form-2/?id=180999&from=3 CLASS PERIOD: January 8, 2024 to ...

期权交易活动分析 - 资金雄厚的投资者对直觉外科公司采取了明显的看跌立场 在监测到的26笔交易中 46%的投资者以看跌预期开仓 而看涨预期开仓的占38% [1] - 监测到的交易包括8笔看跌期权 总金额为592,362美元 以及18笔看涨期权 总金额为1,256,190美元 [1] - 过去30天内 大额交易者的交易活动集中在400美元至700美元的行权价区间内 [2][3] 重要期权交易明细 - 观察到的最大单笔交易为看涨期权 行权价680美元 到期日2026年6月18日 交易价格为23美元 总交易金额为460,000美元 [7] - 一笔重要的看跌期权交易行权价为575美元 到期日2026年2月20日 交易价格为30.15美元 总交易金额为150,700美元 [7] - 另一笔看跌期权交易行权价同样为575美元 到期日2026年2月20日 交易价格为30美元 总交易金额为99,200美元 [7] 公司基本面与市场表现 - 直觉外科公司致力于开发、生产和销售用于辅助微创手术的机器人系统 并提供相关器械、一次性配件和保修服务 [8] - 公司在全球医院部署了超过10,000台达芬奇手术系统 其中美国超过6,000台 新兴市场的安装量正在增长 [8] - 公司股票当前价格为576.0美元 日内上涨0.62% 交易量为696,506股 [13] - 相对强弱指数读数显示该股可能正在接近超买区域 预计31天后发布财报 [13] 分析师观点与价格目标 - 过去30天内 共有3位专业分析师给出评级 平均目标价为645.0美元 [10] - 花旗集团分析师将评级下调至中性 新目标价为635美元 [11] - 加拿大皇家银行资本市场分析师维持跑赢大盘评级 目标价650美元 Truist证券分析师维持买入评级 目标价同样为650美元 [11]

Key Takeaways BD partners with Penn Institute to study 1,000 people, analyzing over 30 immune cell functions in whole blood.The study uses the BD FACSDiscover A8 and Rhapsody systems to decode complex single-cell immune data.The collaboration strengthens BD's focus on advanced flow cytometry and immune profiling research.Becton, Dickinson and Company (BDX) , popularly known as BD, recently announced a collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania t ...

What Happened? LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming February 9, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Integer Holdings Corporation ("Integer†or the "Company†) (NYSE: ITGR) common stock between July 25, 2024 and October 22, 2025, inclusive (the "Class Period†). IF YOU SUFFERED A LOSS ON YOUR INTEGER INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUIN ...

Medtronic plc (NYSE:MDT) is one of the best healthcare AI stocks to buy now. On December 4, Stifel reaffirmed its Hold rating on Medtronic plc (NYSE:MDT), along with a $105 price target. This action came soon after the FDA granted regulatory approval to Medtronic’s HUGO robotic-assisted surgery (RAS) system. Stifel Maintains Hold on Medtronic (MDT) After FDA Approves HUGO System Pixabay/Public Domain Stifel described the HUGO approval as an important and positive step for Medtronic, ending a long develo ...

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the best healthcare AI stocks to buy now. On December 16, David Rescott from Robert W. Baird reaffirmed a Buy rating on Intuitive Surgical, Inc. (NASDAQ:ISRG) and maintained the $655 price target. Earlier on December 11, Citi’s Joanne Wuensch assigned a Hold rating on the stock. Baird Reaffirms Buy on Intuitive Surgical (ISRG) After New FDA Clearances In a different update, on December 10, Intuitive announced that the FDA had cleared its da Vinci Single Po ...

Company Continues to Broaden Leading Wound Product OfferingMARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit®-Wound Gel in the United States. RegenKit®-Wound Gel is an autologous platelet-rich plasma (PRP) and autologous thrombin serum (ATS) wound gel that removes iron-laden red blood cells, while concentrating essential growth factors, f ...

ABBOTT PARK, Ill., Dec. 22, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Voltâ"¢ PFA System to treat patients battling atrial fibrillation (AFib). Abbott will soon begin commercial PFA cases in the United States and will continue its expansion of sites in the European Union following Volt CE Mark approval earlier this year. 12 Minimal number of therapy applications and enhanced patient outcomes. The Volt PFA System is designed ...

Key Takeaways INSP records strong Inspire V adoption, with most implanting centers trained and already using the new system.Inspire Medical expects to improve reimbursement, including an 11% CMS physician fee increase starting in 2026INSP faces near-term pressure from inventory transition, GLP-1 trialing delays, and elevated operating costs.Inspire Medical Systems (INSP) is well poised for growth in the coming quarters amid a major product transition. Management emphasized clinical momentum behind Inspire V ...